6236 Effect of nebulized magnesium sulphate in children with acute exacerbation of bronchial asthma
Notice bibliographique
Résumé
Objectives This study aimed to compare the clinical outcome of nebulized isotonic magnesium sulphate along with standard treatment in hospitalized children with acute exacerbation of asthma who received standard treatment only. Methods A randomized double blind, controlled clinical trial was conducted in medical units of Yankin Children’s Hospital from November 2021 to January 2023. Total ninety-three children who met the inclusion criteria were recruited and randomly assigned to receive either combination of nebulized MgSO4 and salbutamol or combination of nebulized salbutamol and normal saline. Pediatric Respiratory Assessment Measure (PRAM) score was used to assess improvement before and after intervention.1 2 Each group received either nebulized MgSO4 or nebulized salbutamol for three times at 20 min interval.1–3 The changes in score and other short-term measures such as additional requirement for intravenous bronchodilators and additional nebulized salbutamol and length of stay in hospital were observed. Results The major findings of the study were an overall faster reduction in the symptomatic scores as measured with PRAM scores, hospital stay and requirement of additional nebulizer doses in children who received combination of nebulized MgSO4 and salbutamol compared to those who received combination of nebulized salbutamol and normal saline. In this study, post-inhalation clinical severity score was significantly lower than pre-inhalation values for both groups during study period. Improvement percentage of clinical severity score was better in study group than control group. However, additional intravenous bronchodilator requirement is not different between two study groups. The mean length of stay in hospital also differed significantly between the two groups 1.48 ± .781 days in nebulized Magnesium Sulphate and salbutamol combination group and 4.63 ± 2.727 days in nebulized salbutamol and saline group. Conclusion This study clearly demonstrated that the study group was superior in improvement of severity clinical score and also shorter length of stay in hospital. In addition, there was no difference in safety profile between two groups. References Alansari K, Ahmed W, Davidson BL, Alamri M, Zakaria I, Alrifaai M. Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial: Pediatr Pulmonol: 2015;50: 1191–1199. Gourgoulianis KI, Chatziparasidis G, Chatziefthimiou A, Molyvdas PA. Magnesium as a relaxing factor of airway smooth muscles. Journal of Aerosol Medicine 2001a;14:301–307. Powell C, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, Hood K, Williamson P. Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. The Lancet Respiratory Medicine 2013;1:301–30. Powell CVE, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, et al. (2013) MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children. Health Technol Assess 2013;17(45). Schuh S, Sweeney J, Rumantir M, Coates AL, Willan AR, Stephens D, Atenafu EG, Finkelstein Y, Thompson G, Zemek R. Pediatric Emergency Research Canada (PERC) Network. Effect of Nebulized Magnesium vs placebo added to albuterol on hospitalization among children with refractory acute asthma treated in the emergency department. JAMA 2020;324:2038–2047.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,002 | 0,001 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».